 "Vaccine")
US-based vaccine major Novavax on Friday said along with its Indian partner Serum Institute of India (SII) it would supply 1.1 billion doses of Covid vaccine to Gavi-led COVAX.
The vaccine candidate NVX-CoV2373 has demonstrated clinical efficacy against the original Covid-19 strain and both of the rapidly emerging variants in the UK and South Africa.
Novavax licensed its NVX-CoV2373 vaccine technology to SII with no upfront, milestone or technology transfer payments. Novavax will supply the doses to high-income countries while SII will supply to the majority of the low-, middle-income and upper-middle income countries utilising a ‘tiered pricing
The vaccine candidate NVX-CoV2373 has demonstrated clinical efficacy against the original Covid-19 strain and both of the rapidly emerging variants in the UK and South Africa.
Novavax licensed its NVX-CoV2373 vaccine technology to SII with no upfront, milestone or technology transfer payments. Novavax will supply the doses to high-income countries while SII will supply to the majority of the low-, middle-income and upper-middle income countries utilising a ‘tiered pricing
